Det øgede dosisinterval for Truvada hos patienter med moderat nedsat nyrefunktion forventes at resultere i højere peak- plasmakoncentrationer og lavere Cmin- niveauer sammenlignet med patienter med normal nyrefunktion.
The increased dose interval for Truvada in patients with moderate renal impairment is expected to result in higher peak plasma concentrations and lower Cmin levels as compared to patients with normal renal function.